Brief Report: Severe Sotorasib-Related Hepatotoxicity and Non-Liver Adverse Events Associated With Sequential Anti–Programmed Cell Death (Ligand)1 and Sotorasib Therapy in KRASG12C-Mutant Lung Cancer
Ali Chour, Julie Denis, Céline Mascaux, M. Zysman, L. Bigay-Gamé, Aurélie Swalduz, V. Gounant, Alexis B. Cortot, Marie Darrason, Vincent Fallet, Édouard Auclin, Clémence Basse, Claire Tissot, C. Decroisette, P. Bombaron, Etienne Giroux‐Leprieur, L. Odier, Solenn Brosseau, Quentin Creusot, M. Gueçamburu, Corentin Meersseman, Adrien Rochand, Adrien Costantini, Claire Marine Gaillard, Eric Wasielewski, Nicolas Girard, Jacques Cadranel, Claire Lafitte, Fanny Lebossé, M. Duruisseaux
Topics & Concepts
MedicineLung cancerAdverse effectMutantOncologyLigand (biochemistry)Programmed cell deathLungTargeted therapyCancerApoptosisInternal medicineCancer researchReceptorBiochemistryGeneChemistryCancer Immunotherapy and BiomarkersLung Cancer Treatments and MutationsLung Cancer Research Studies